Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab
Dermatitis® · 01.02.2024 · 35 (1_suppl)
DOI: 10.1089/derm.2023.0052 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatitis®, online erschienen am 18.08.2023. Verfasst von Vittoria Cioppa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, S. Maria alle Scotte Hospital, Siena, Italy. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, S. Maria alle Scotte Hospital, Siena, Italy.
- Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
- Dermatological Research Hospital, IDI-IRCCS, Rome, Italy.
Zitieren
APA
Cioppa, V., Lazzeri, L., Carraro, A., De Piano, E., Falcinelli, F., Galluzzo, M., Pallotta, S., De Pità, O., & Russo, F. (2024). Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab. Dermatitis®, 35(1_suppl). https://doi.org/10.1089/derm.2023.0052
Vancouver
Cioppa V, Lazzeri L, Carraro A, De Piano E, Falcinelli F, Galluzzo M, et al. Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab. Dermatitis®. 2024;35(1_suppl). doi:10.1089/derm.2023.0052
BibTeX
@article{Cioppa2024,
author = {Cioppa, Vittoria and Lazzeri, Laura and Carraro, Andrea and De Piano, Ernesto and Falcinelli, Francesca and Galluzzo, Marco and Pallotta, Sabatino and De Pità, Ornella and Russo, Filomena},
title = {Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab},
journal = {Dermatitis®},
year = {2024},
volume = {35},
number = {1_suppl},
doi = {10.1089/derm.2023.0052}
}
EUVIMED